Subscribe to RSS
DOI: 10.1055/a-2004-4449
Entwicklung der Insulintherapie in der pädiatrischen Diabetologie- Auswertung des DPV-Registers von 1995-2021
Development of insulin therapy in paediatric diabetology- analysis from the DPV registry (1995-2021)Supported by: Deutsche Diabetes-Gesellschaft (DDG)Supported by: Deutsches Zentrum für Diabetesforschung 82DZD14E03
Supported by: Diabetes-Surveillance des RKI
Zusammenfassung
Der Einsatz von Insulin zur Therapie des Diabetes mellitus Typ 1 beim Menschen hat vor 100 Jahren erstmals zum Überleben betroffener Patienten nach Manifestation der Erkrankung geführt. War zuvor die Diagnose mit der Gewissheit verknüpft, dass es sich um eine unmittelbar lebensbedrohliche Erkrankung handelt, wurde mit dem Einsatz des Hormons Insulin ab 1922 die Perspektive eröffnet, den Verlauf der Erkrankung zu beeinflussen und die Prognose für die Patienten damit zu verbessern.
Ziel der vorliegenden Arbeit ist die Analyse von 92366 Patienten eines pädiatrischen Patientenkollektivs aus Deutschland, Österreich, Luxemburg und der Schweiz im Hinblick auf den Einsatz der verschiedenen Insulinarten im Zeitraum 1995–2021.
Der Anteil der Insulinanaloga stieg insbesondere seit dem Jahr 2000 stark an, auch da die Nutzung von Insulinpumpen mit Analoginsulin im Vergleich zur intensivierten Insulintherapie mit Pen für alle Altersgruppen deutlich anstieg. Bereits im Jahr 2010 betrug der Anteil der Insulinanaloga in der Diabetestherapie bei Kindern insgesamt > 60 %.
Im Jahr 2022 können Diabetologen auf mehr als zehn Insulinarten und mindestens fünf verschiedene Therapieformen zur Behandlung des Diabetes mellitus Typ 1 zurückgreifen.
Abstract
One hundred years ago, the use of insulin to treat type 1 diabetes mellitus in humans led to the survival of affected patients. While the diagnosis was previously linked to the certainty that the disease was immediately life-threatening, the use of the hormone insulin from 1922 on opened the prospect of positively influencing the course of the disease and thus improving the prognosis for the patients.
The aim of this work is the analysis of 92,366 patients in a pediatric patient collective from Germany, Austria, Luxembourg, and Switzerland focusing on the use of the various types of insulin from 1995–2021.
The proportion of insulin analogues has increased rapidly since 2000, also because the use of insulin pumps with analogue insulin compared to intensified insulin therapy via pen increased significantly for all age groups. In 2010, the use of insulin analogues in diabetes therapy in children was > 60%.
In 2022, diabetologists have access to more than ten types of insulin and at least five different forms of therapy to treat type 1 diabetes mellitus.
Publication History
Received: 07 November 2022
Accepted: 28 December 2022
Article published online:
13 January 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Karamitsos DT. The story of insulin discovery. Diabetes Research and Clinical Practice 2011; 93 (Suppl. 01) S2-S8 DOI: 10.1016/s-0168-8227(11)70007-9. (PMID: 21864746)
- 2 Hirsch IB. Insulin analogues. N Engl J Med 2005; 352 (02) 174-183 DOI: 10.1056/NEJMra040832. (PMID: 15647580)
- 3 Borgoño CA, Zinman B. Insulins: past, present, and future. Endocrinol Metab Clin North Am 2012; 41 (01) 1-24 DOI: 10.1016/j.ecl.2012.03.002. (PMID: 22575404)
- 4 Kordonouri O, Danne T. Insulintherapie bei Kindern und Jugendlichen. Diabetologe 2008; 4: 499-505 DOI: 10.1007/s11428-008-0246-3.
- 5 Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr Drugs 2014; 16 (02) 141-150 DOI: 10.1007/s40272-014-0064-6.. (PMID: 24458650)
- 6 Tibaldi JM. Evolution of insulin: from human to analog. Am J Med 2014; 127 (Suppl. 10) S25-S38 DOI: 10.1016/j.amjmed.2014.07.005. (PMID: 25282010)
- 7 Eckert A, Bramlage P, Danne T. et al. Verwendung von Insulinpräparaten – Auswertung des DPV-Registers. Dtsch Arztebl Int 2022; 119: 649-650 DOI: 10.3238/arztebl.m2022.0253.
- 8 Bohn B, Karges B, Vogel Ch. et al. 20 Years of Paediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type1 diabetes. PLoS ONE 2016; 11 (08) e0160971 DOI: 10.1371/journal.pone.0160971.
- 9 Prinz N, Lange K. Holl RW für das DPV-Register der pädiatrischen Diabetologie und die AGPD, Kinder und Jugendliche mit Diabetes – aktuelle Versorgungssituation und Veränderungen der letzten 26 Jahre, Deutscher Gesundheitsbericht Diabetes. 2022
- 10 Marg W, Rami-Merhar B, Casteels K. et al. Versorgung von Diabetes mellitus im Kindes- und Jugendalter, heute und morgen: ein Blick auf Deutschland im Vergleich zu Belgien, Österreich und der Schweiz. Monatsschr Kinderheilkd 2022; 170: 412-421 DOI: 10.1007/s00112-019-00836-4.
- 11 White MF, Kahn CR. Insulin action at a molecular level – 100 years of progress. Mol Metab 2021; 52: 101304 DOI: 10.1016/j.molmet.2021.101304. (PMID: 34274528)
- 12 Karges B, Schwandt A, Heidtmann B. et al. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA 2017; 318 (14) 1358-1366 DOI: 10.1001/jama.2017.13994.
- 13 Wang X, Zhao X, Chen D. et al. Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Pediatric Type 1 Diabetes: A Meta-Analysis and Prospective Cohort Study. Front Endocrinol 2021; 12: 608232 DOI: 10.3389/fendo.2021.608232. (PMID: 33737909)
- 14 Haynes A, Hermann JM, Clapin H. et al. WACDD and DPV registries. Decreasing Trends in Mean HbA1c Are Not Associated with Increasing Rates of Severe Hypoglycemia in Children: A Longitudinal Analysis of Two Contemporary Population-Based Pediatric Type 1 Diabetes Registries from Australia and Germany/Austria Between 1995 and 2016. Diabetes Care 2019; 42 (09) 1630-1636 DOI: 10.2337/dc18-2448.
- 15 Kamrath C, Tittel SR, Kapellen TM. et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health 2021; 5 (01) 17-25 DOI: 10.1016/S2352-4642(20)30339-4.
- 16 Alvarenga CS, La Banca RO, Neris RR. et al. Continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes mellitus: a systematic mapping review. BMC Endocr Disord 2022; 22 (01) 43 DOI: 10.1186/s12902-022-00950-7.
- 17 Biester T, Kordonouri O, Danne T. Pharmacological Properties of Faster-Acting Insulin Aspart. Curr Diab Rep 2017; 17 (11) 101 DOI: 10.1007/s11892-017-0931-y. (PMID: 28940145)
- 18 Heise T, Zijlstra E, Nosek L. et al. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial. Diabetes Obes Metab 2017; 19 (02) 208-215 DOI: 10.1111/dom.12803.
- 19 Heise T, Linnebjerg H, Coutant D. et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab 2020; 22 (10) 1789-1798 DOI: 10.1111/dom.14094. (PMID: 32436641)
- 20 Steck AK, Klingensmith GJ, Fiallo-Scharer R. Recent advances in insulin treatment of children. Pediatr Diabetes 2007; 8 (Suppl. 06) S49-S56 DOI: 10.1111/j.1399-5448.2007.00276.x. (PMID: 17727385)
- 21 Miles HL, Acerini CL. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008; 10 (03) 163-176 DOI: 10.2165/00148581-200810030-00005. (PMID: 18454569)
- 22 Werner H, Chantelau EA. Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years. Diabetol Metab Syndr 2011; 3 (01) 13 DOI: 10.1186/1758-5996-3-13. (PMID: 21714872)
- 23 Galli-Tsinopoulou A, Stergidou D. Insulin analogues for type 1 diabetes in children and adolescents. Drugs Today 2012; 48 (12) 795-809 DOI: 10.1358/dot.2012.48.12.1872944. (PMID: 23243636)
- 24 Richter B, Neises G. Human insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005; 2005 (01) CD003816 DOI: 10.1002/14651858.CD003816.pub2. (PMID: 15674916)
- 25 Fullerton B, Siebenhofer A, Jeitler K. et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; 2016 (06) CD012161 DOI: 10.1002/14651858.CD012161. (PMID: 27362975)
- 26 Hemmingsen B, Metzendorf MI, Richter B. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Cochrane Database Syst Rev 2021; 3 (03) CD013498 DOI: 10.1002/14651858.CD013498.pub2. (PMID: 33662147)
- 27 Karges B, Kapellen T, Neu A. et al. Diabetes Prospective Documentation DPV Initiative; German Federal Ministry for Education and Research BMBF Competence Network of Diabetes Mellitus. Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a prospective study of 10,682 patients from 271 institutions. Diabetes Care 2010; 33 (05) 1031-1033 DOI: 10.2337/dc09-2249. (PMID: 22128781)
- 28 Kapellen TM. Update Typ-1-Diabetes bei Kids: Insuline, Technologie, Telemedizin. Info Diabetol 2021; 15 (05) 42-50 DOI: 10.1007/s15034-021-3755-4.
- 29 Galli-Tsinopoulou A. Insulin therapy in children and adolescents with diabetes. Diabetes Research and Clinical Practice 2011; 93 (Suppl. 01) S114-S117 DOI: 10.1016/S0168-8227(11)70026-2. (PMID: 21864742)
- 30 Phillips LK, Phillips PJ. Innovative insulins--where do analogues fit?. Aust Fam Physician 2006; 35 (12) 969-973 (PMID: 17149471)
- 31 Biester T, Kapitzke K, Danne T. et al. Pharmakotherapie des Diabetes bei Kindern und Jugendlichen. Arzneimitteltherapie 2017; 35: 157-165
- 32 Division of Medicines and Health Products in collaboration with the Division of Communicable and Noncommunicable Diseases at WHO Headquarters. Keeping the 100-year-old promise: making insulin access universal. World Health Organization. 2021
- 33 Van Nuys K, Ribero R, Ryan M. et al. Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018. JAMA Health Forum 2021; 2 (11) e213409 DOI: 10.1001/jamahealthforum.2021.3409.
- 34 Cengiz E, Danne T, Ahmad T. et al. ISPAD CLINICAL PRACTICE CONSENSUS GUIDELINES 2022: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2022; 23 (08) 1277-1296 DOI: 10.1111/pedi.13442.